Colloidal Silver, Treatment of COVID-19

SARS (Severe Acute Respiratory Syndrome) Clinical Trial

Official title:

The Value of Colloidal Silver in the Treatment of COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04978025
• Other study ID #: colloidal silver and COVID-19
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2020
• Est. completion date: November 1, 2021

Study information

• Verified date: July 2021
• Source: Hôpital Universitaire Sahloul
• Contact: Boukef Riadh, professor
• Phone: 00 216 98 676 745
• Email: riadboukef[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I

Description:

Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy.

The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 1, 2021
• Est. primary completion date: November 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.

Exclusion Criteria:

• Any pregnant or breastfeeding woman

• patient with an expectation of survival of less than 24 hours

• Dyspnea leading to heart failure

• Hepatic insufficiency

• Chronic respiratory failure

• Renal failure, clearance <20ml • min-1 • 1.73 • m-²

Related Conditions & MeSH terms

• SARS (Severe Acute Respiratory Syndrome)
• Severe Acute Respiratory Syndrome

Intervention

Drug:
• Colloidal Silver
Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon) and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
• Placebo
Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.

Locations

Country	Name	City	State
Tunisia	HU Sahloul, sousse, Tunisia	Sousse	Itinéraire Ceinture Cité Sahloul

Sponsors (1)

Lead Sponsor	Collaborator
Hôpital Universitaire Sahloul

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chage of clinical status	the distribution of clinical status assessed on the 7-point ordinal scale on day 10 of the study	10 DAYS
Secondary	Adverse events	adverse events throughout the study period	ON 1 month
Secondary	the duration of hospitalization	number of days of hospitalization	ON 11 days
Secondary	the duration of the different respiratory assistance modes	the duration of the different respiratory assistance modes	ON 11 days
Secondary	all-cause mortality	the cause and the date of Death	ON 1 month